Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Doustny glibenklamid w leczeniu przedwczesnej hiperglikemii (GALOP) (GALOP)

1 października 2026 zaktualizowane przez: Assistance Publique - Hôpitaux de Paris

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Przegląd badań

Szczegółowy opis

Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

35

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Paris, Francja, 75015
        • Hopital Necker - Enfants malades

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

Nie starszy niż 7 miesięcy (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Newborn less than 34 week of amenorrhea corrected age
  • Birth weight < 1500 g
  • Birth term < 32 week of amenorrhea
  • Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
  • Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
  • Enteral feeding considered before inclusion or already established
  • Consent obtained from persons holding parental authority
  • Beneficiary of social security

Exclusion Criteria

  • Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
  • Contraindication to glibenclamide according to current SPC
  • Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
  • Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
  • Severe sepsis requiring mechanical ventilation or haemodynamic support
  • Severe renal dysfunction (serum creatinine > 120 µmol/l)
  • Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
  • Hyperglycemia associated with an error in administering glucose infusion
  • Profound hypophosphoremia (< 1 mmol/l)
  • Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
  • Patient with continuous insulin IV administration
  • Patient treated with miconazole

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Glibenclamide oral

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

  • For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);
  • For subsequent patients included during phase II:
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment
  • 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.
  • In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.

PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution.

blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized

If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Transaminases and hemostasis will be done only in case of clinical indication before the first administration.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Blood glucose control
Ramy czasowe: At 72 hours after the first administration

The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours)

At 72 hours after the first administration

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Overall success of the treatment
Ramy czasowe: At 36 week of amenorrhea corrected age

Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin.

At 36 week of amenorrhea corrected age
Blood glucose profile on glibenclamide
Ramy czasowe: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Ramy czasowe: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Ramy czasowe: At the end of treatment assessed up to 15 days

Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Ramy czasowe: At the end of treatment assessed up to 15 days

Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Ramy czasowe: At the end of treatment assessed up to 15 days

Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Duration of glibenclamide treatment
Ramy czasowe: At the end of treatment assessed up to 15 days

Duration of glibenclamide treatment.

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Ramy czasowe: At the end of treatment assessed up to 15 days

Carbohydrate

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Ramy czasowe: At the end of treatment assessed up to 15 days

lipid

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Ramy czasowe: At the end of treatment assessed up to 15 days

protein

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Ramy czasowe: At the end of treatment assessed up to 15 days

mean caloric intake (kcal/kg/day) during treatment

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Ramy czasowe: At the end of treatment assessed up to 15 days

mean weight gain (g/kg/day)

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Ramy czasowe: At 36 week of amenorrhea corrected age

Carbohydrate

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Ramy czasowe: At 36 week of amenorrhea corrected age

lipid

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Ramy czasowe: At 36 week of amenorrhea corrected age

protein

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Ramy czasowe: At 36 week of amenorrhea corrected age

mean caloric intake (kcal/kg/day) during treatment

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Ramy czasowe: At 36 week of amenorrhea corrected age

mean weight gain ((g/kg/day)

At 36 week of amenorrhea corrected age
Number of children with episode of hypoglycemia
Ramy czasowe: At 72 hours after first administration

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At 72 hours after first administration
Number of children with episode of hypoglycemia
Ramy czasowe: At the end of treatment assessed up to 15 days

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At the end of treatment assessed up to 15 days
Type of adverse reactions on glibenclamide
Ramy czasowe: At 36 week of amenorrhea corrected age

evaluation of the type of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of adverse reactions on glibenclamide
Ramy czasowe: At 36 week of amenorrhea corrected age

evaluation of number of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of participants with co-morbidity
Ramy czasowe: At 36 week of amenorrhea corrected age

Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis

At 36 week of amenorrhea corrected age
Mortality
Ramy czasowe: At 36 week of amenorrhea corrected age

Mortality will be assessed

At 36 week of amenorrhea corrected age
Dose adjustment
Ramy czasowe: At the end of treatment assessed up to 15 days

Number of dose adjustments, to evaluate the easy of use

At the end of treatment assessed up to 15 days
ease of use by caregivers
Ramy czasowe: At day one of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day one of treatment
ease of use by caregivers
Ramy czasowe: At day two of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day two of treatment
ease of use by caregivers
Ramy czasowe: At day three of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day three of treatment
Plasma concentrations of glibenclamide
Ramy czasowe: At 3 hours after the first administration

Evaluated by the pharmacokinetics study

At 3 hours after the first administration
Plasma concentrations of glibenclamide
Ramy czasowe: At 6 hours after the first administration

Evaluated by the pharmacokinetics study

At 6 hours after the first administration
Plasma concentrations of glibenclamide
Ramy czasowe: At 10 hours after the first administration

Evaluated by the pharmacokinetics study

At 10 hours after the first administration
Plasma concentrations of glibenclamide
Ramy czasowe: At 24 hours after the first administration

Evaluated by the pharmacokinetics study

At 24 hours after the first administration
Plasma concentrations of glibenclamide
Ramy czasowe: At 24 hours of blood glucose stabilization

Evaluated by the pharmacokinetics study

At 24 hours of blood glucose stabilization

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
  • Dyrektor Studium: Michel POLAK, Assistance Publique - Hôpitaux de Paris
  • Dyrektor Studium: Delphine MITANCHEZ, CHRU de Tours

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

20 maja 2023

Zakończenie podstawowe (Rzeczywisty)

30 października 2025

Ukończenie studiów (Rzeczywisty)

8 stycznia 2026

Daty rejestracji na studia

Pierwszy przesłany

7 grudnia 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 stycznia 2023

Pierwszy wysłany (Rzeczywisty)

18 stycznia 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

2 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

1 października 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj